Get the Stockscreener App
0.8984
4.46%
-0.0419
Renovorx Inc stock is traded at $0.8984, with a volume of 140.58K.
It is down -4.46% in the last 24 hours and down -29.26% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$0.9403
Open:
$0.94
24h Volume:
140.58K
Relative Volume:
0.75
Market Cap:
$32.86M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-1.5761
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
-4.43%
1M Performance:
-29.26%
6M Performance:
-7.37%
1Y Performance:
-11.03%
1-Day Range:
$0.8903
$0.94
1-Week Range:
$0.80
$0.965
52-Week Range:
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.8984 | 34.38M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovorx Inc Stock (RNXT) Latest News
Chartists Watching For Breakout in RenovoRx Inc.2025 Market Overview & Real-Time Volume Surge Alerts - newsyoung.net
Annual Global Investment Conference in New York City, September 8-10, 2025 - Business Wire
RenovoRx Inc. Breakout Confirmed by Volume MetricsMarket Activity Recap & Accurate Buy Signal Alerts - thegnnews.com
Buy Rating Affirmed for RenovoRx Amid Promising Phase 3 Study Progress and Potential Stock Catalyst - TipRanks
RenovoRx, Inc. (NASDAQ:RNXT) Q2 2025 Earnings Call Transcript - MSN
Trend Dashboard Flags RenovoRx Inc. As Potential Swing TradeJuly 2025 Action & Fast Moving Market Watchlists - 선데이타임즈
RenovoRx's Promising Product Launch and Strategic Expansion Drive Analyst's Buy Rating - AInvest
RenovoRx Inc. Rebound Backed by Sentiment ShiftJuly 2025 Chart Watch & Reliable Intraday Trade Alerts - newsimpact.co.kr
RenovoRx’s Promising Product Launch and Strategic Expansion Drive Buy Rating - TipRanks
RenovoRx Earnings Miss Highlights Short-Term Volatility, Signals Longer-Term Recovery Potential - AInvest
RenovoRx (RNXT.O) Plummets 22.9%—What’s Behind the Sudden Drop? - AInvest
RenovoRx Q2 Earnings Miss Sparks Immediate Sell-Off, But Long-Term Backtest Suggests Recovery Potential - AInvest
Does RenovoRx Inc. have consistent dividend growth2025 Short Interest & High Yield Stock Recommendations - sisa-n.com
What the charts say about RenovoRx Inc. todayTrade Entry Summary & High Yield Equity Trading Tips - Newser
Backtesting results for RenovoRx Inc. trading strategiesJuly 2025 Decliners & Verified Swing Trading Watchlists - Newser
Can trapped investors hope for a rebound in RenovoRx Inc.Dividend Hike & Technical Buy Zone Confirmation - Newser
Price momentum metrics for RenovoRx Inc. explainedTrade Signal Summary & Real-Time Stock Price Movement Reports - Newser
What indicators show strength in RenovoRx Inc.2025 Key Highlights & Detailed Earnings Play Alerts - Newser
What makes RenovoRx Inc. stock price move sharplyTrade Entry Summary & Scalable Portfolio Growth Ideas - Newser
Here's Why We're Watching RenovoRx's (NASDAQ:RNXT) Cash Burn Situation - simplywall.st
What data driven models say about RenovoRx Inc.’s futureSell Signal & Free Safe Capital Growth Stock Tips - Newser
Will RenovoRx Inc. price bounce be sustainable2025 AllTime Highs & Stepwise Trade Signal Implementation - Newser
Is RenovoRx Inc. stock bottoming outTrade Risk Summary & Long-Term Safe Investment Ideas - Newser
Visual trend scoring systems applied to RenovoRx Inc.Gap Up & Smart Allocation Stock Tips - Newser
RenovoRx Revenue Jumps 28 Percent in Q2 - sharewise.com
RenovoRx’s PanTheR Registry Trial: A Promising Update for Investors - MSN
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates - MSN
Why RenovoRx Inc. stock attracts strong analyst attentionLong Setup & Target Return Focused Stock Picks - thegnnews.com
Is this a good reentry point in RenovoRx Inc.Global Markets & Reliable Intraday Trade Plans - Newser
RenovoRx Reports Strong Q2 2025 Revenue Growth - The Globe and Mail
Machine Learning Models Forecast RenovoRx Inc. UptickWeekly Trade Report & Daily Profit Focused Stock Screening - beatles.ru
RenovoRx Plummets 22.8% Intraday: Is This a Catalyst-Driven Collapse or a Buying Opportunity? - AInvest
RenovoRx Exceeds Revenue Estimates with $422,000 Q2 2025 Earnings, Net Loss Widens to $2.9 Million - AInvest
RenovoRx Reports Q2 2025 Revenue Growth, TIGeR-PaC Trial Continues with Positive Recommendation - AInvest
How to recover losses in RenovoRx Inc. stock2025 Earnings Impact & Weekly High Potential Stock Alerts - Newser
RenovoRx Inc (RNXT) Q2 2025 Earnings Call Highlights: Strong Market Demand and Strategic Trials ... - Yahoo Finance
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review - BioSpace
RenovoRx Reports Revenue Growth and Trial Progress - TipRanks
RenovoRx (RNXT): Navigating Short-Term Losses for Long-Term Oncology Breakthroughs - AInvest
RenovoRx Inc. Added to High Probability Setup List2025 Market Overview & Daily Stock Trend Watchlist - metal.it
Earnings call transcript: RenovoRx Q2 2025 reveals revenue challenges By Investing.com - Investing.com Canada
RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Earnings call transcript: RenovoRx Q2 2025 reveals revenue challenges - Investing.com
RenovoRx earnings beat, revenue fell short of estimates - Investing.com
RenovoRx Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Using Ichimoku Cloud for RenovoRx Inc. technicalsQuarterly Trade Review & Reliable Breakout Forecasts - Newser
Moving Average Crossover Confirms Uptrend in RenovoRx Inc.2025 Geopolitical Influence & AI Powered Market Entry Ideas - thegnnews.com
Using data filters to optimize entry into RenovoRx Inc.Options Play & Fast Gain Stock Trading Tips - Newser
Will RenovoRx Inc. continue its uptrendJuly 2025 Institutional & High Conviction Buy Zone Picks - Newser
Can swing trading help recover from RenovoRx Inc. lossesMarket Movers & AI Enhanced Execution Alerts - Newser
Will RenovoRx Inc. continue its uptrend [Market Performance Recap]Community Trade Idea Sharing - Newser
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Renovorx Inc Stock (RNXT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marton Laurence | Director |
May 02 '25 |
Option Exercise |
0.15 |
20,480 |
3,072 |
66,164 |
| Agah Ramtin | Chief Medical Officer |
Apr 15 '25 |
Buy |
0.90 |
15,000 |
13,500 |
1,113,460 |
| Bagai Shaun | Chief Executive Officer |
Apr 15 '25 |
Buy |
0.91 |
7,500 |
6,821 |
320,040 |
| Agah Ramtin | Chief Medical Officer |
Apr 11 '25 |
Buy |
0.80 |
20,000 |
16,000 |
1,098,460 |
| Kocak Ron | VP Controller and PAO |
Apr 10 '25 |
Buy |
0.79 |
6,500 |
5,135 |
12,595 |
| Kocak Ron | VP Controller and PAO |
Apr 09 '25 |
Buy |
0.80 |
6,000 |
4,800 |
6,095 |
| Kocak Ron | VP Controller and PAO |
Apr 08 '25 |
Buy |
0.80 |
95 |
76 |
95 |
| Agah Ramtin | Chief Medical Officer |
Apr 09 '25 |
Buy |
0.81 |
30,000 |
24,399 |
1,078,460 |
| Bagai Shaun | Chief Executive Officer |
Apr 09 '25 |
Buy |
0.83 |
10,000 |
8,300 |
312,540 |
| Marton Laurence | Director |
Apr 08 '25 |
Buy |
0.85 |
12,050 |
10,218 |
45,684 |
1.38%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):